<DOC>
	<DOC>NCT00212654</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in postoperative supraventricular tachyarrhythmias.</brief_summary>
	<brief_title>Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan</brief_title>
	<detailed_description />
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Landiolol</mesh_term>
	<criteria>1. 20 years or older 2. Postoperative supraventricular tachyarrhythmias 3. Within 7 days postoperatively 4. Other inclusion criteria as specified in the protocol 1. Acute myocardial infarction (within 1 month after onset) 2. Severe heart failure [New York Heart Association (NYHA) functional class III or higher] 3. Atrioventricular block (grade II or higher), or sick sinus syndrome 4. Other exclusion criteria as specified in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>ONO-1101</keyword>
	<keyword>Landiolol Hydrochloride</keyword>
	<keyword>Postoperative</keyword>
	<keyword>supraventricular tachyarrhythmia</keyword>
</DOC>